NEWS
Latest from Sainc
Milestones on our engineered-yeast platform, our EU funding applications and our partnerships.

NOVEMBER 2026
TRISOMALT full proposal submitted to the EIC Accelerator
Sainc has submitted its full proposal for TRISOMALT to the European Innovation Council (EIC) Accelerator, the EU’s flagship programme for breakthrough deep-tech companies.
TRISOMALT takes our patented three-sugar platform to industrial scale. A single engineered strain of Komagataella phaffii converts ordinary sucrose into three products: isomaltulose (EDULCOSE™), a low-glycaemic sugar for food and drinks; trehalulose (Mieltopone™), a honey-like low-glycaemic sweetener; and isomalt for sugar-free confectionery. The process has been proven at pilot scale, and the project would fund the step to an industrial plant, with a letter of intent for offtake from a European sweetener buyer already in place.

JULY 2026
TRISOMALT rated “Excellent” on all four criteria at EIC Accelerator Step 1
Before a company can submit a full EIC Accelerator proposal, its short proposal is assessed by independent evaluators at Step 1. TRISOMALT was rated “Excellent” on all four criteria, which opened the way to the full proposal.
The evaluators’ result confirms the strength of the platform: enzymes displayed on the surface of the yeast, which keeps the catalyst stable, makes separation simple and lets one host produce a family of products. It is protected by an international patent application (PCT/IB2024/059737, published as WO2025/099508) with UK, European and Indian filings, and backed by a deposited strain (BCCM/MUCL 58379).

FEBRUARY 2026
UK biomanufacturing delegation to India
Sainc was one of 20 UK biomanufacturing and pharmaceutical SMEs selected for a delegation to Mumbai and Hyderabad, led by the Centre for Process Innovation (CPI), a founding member of the High Value Manufacturing Catapult, with the British High Commission in India. Under the UK–India Vision 2035 framework, the mission set out to speed up international scale-up, supply-chain access and joint R&D.
In Mumbai the delegation presented at CHEMTECH World Expo 2026 and met government officials, pharmaceutical companies, investors and potential partners. In Hyderabad it held technical visits and roundtables at IKP Knowledge Park and the Centre for DNA Fingerprinting and Diagnostics on joint research, biomanufacturing scale-up and commercialisation.
Building on the visit, CPI signed a Letter of Intent with India’s Biotechnology Research and Innovation Council (BRIC) in October 2026 to formalise long-term UK–India collaboration in biomanufacturing. For Sainc, India is a natural market for low-glycaemic sugars, and our technology is the subject of an Indian patent filing. To discuss partnering in India, please contact us.
